Eurasian clinical guidelines for the diagnosis and treatment of secondary (symptomatic) forms of arterial hypertension (2022)

Disclaimer. The EAC Guidelines represent the views of the EAC, and were produced after careful consideration of the scientific and medical knowledge, and the evidence available at the time of their publication. The EAC is not responsible in the event of any contradiction, discrepancy, and/or ambiguity between the EAC Guidelines and any other official recommendations or guidelines issued by the relevant public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encouraged to take the EAC Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic, or therapeutic medical strategies; however, the EAC Guidelines do not override, in any way whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient’s health condition and in consultation with that patient and, where appropriate and/or necessary, the patient’s caregiver. Nor do the EAC Guidelines exempt health professionals from taking into full and careful consideration the relevant official updated recommendations or guidelines issued by the competent public health authorities, in order to manage each patient’s case in light of the scientifically accepted data pursuant to their respective ethical and professional obligations. It is also the health professional’s responsibility to verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription.

1. Egan B.M., Kjeldsen S.E., Grassi G. et al. The global burden of hypertension exceeds 1.4 billion people: should a systolic blood pressure target below 130 become the universal standard? J Hypertens. 2019;37(6):1148- 1153. doi: 10.1097/HJH.0000000000002021

2. Viera A.J., Neutze D.M. Diagnosis of secondary hypertension: an age-based approach. Am Fam Physician. 2010;82(12):1471-1478

3. Williams B., Mancia G., Spiering W. et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension [published correction appears in J Hypertens. 2019 Jan;37(1):226]. J Hypertens. 2018;36(10):1953-2041. doi: 10.1097/HJH.0000000000001940

4. Chazova I.E., Zhernakova Yu.V. on behalf of the experts. Clinical guidelines. Diagnosis and treatment of arterial hypertension. Systemic Hypertension. 2019;16(1):6–31 (in Russ). doi: 10.26442/2075082X.2019.1.190179

5. Calhoun D.A., Jones D., Textor S. et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008;117(25):e510–526. doi: 10.1161/CIRCULATIONAHA.108.189141

6. Carey R.M., Calhoun D.A., Bakris G.L. et al. Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association. Hypertension. 2018;72(5):e53-e90. doi: 10.1161/HYP.0000000000000084

7. Aksenova A.V., Sivakova O.A., Blinova N.V. et al. Russian Medical Society for Arterial Hypertension expert consensus. Resistant hypertension: detection and management. Terapevticheskii arkhiv. 2021;93(9):1018–1029. doi: 10.26442/00403660.2021.09.201007

8. Rimoldi S.F., Scherrer U., Messerli F.H. Secondary arterial hypertension: when, who, and how to screen? Eur Heart J. 2014 May 14;35(19):1245- 54. doi: 10.1093/eurheartj/eht534

9. Arabidze G.G. Symptomatic arterial hypertension. In: Diseases of the heart and blood vessels. Ed. E.I. Chazov. - M.: Medicine, 1992;3:196-226. (in Russ).

10. Cingolani O.H. Cardiovascular risks and organ damage in secondary hypertension. Endocrinol Metab Clin North Am. 2019 Dec;48(4):657- 666. doi: 10.1016/j.ecl.2019.08.015

11. Ratner N.A. Arterial hypertension. M.: Medicine, 1974. – 415p. (in Russ).

12. 12 Chikhladze N.M. Symptomatic (secondary) arterial hypertension: diagnosis and treatment. Moscow: Medical Information Agency, 2018. — 168. (in Russ.). ISBN 978-5-907098-01-5

13. Young W.F. Jr., Calhoun D.A., Lenders J.W.M. et al. Screening for Endocrine Hypertension: An Endocrine Society Scientific Statement, Endocrine Reviews, 2017;38(2):103–122. doi: 10.1210/er.2017-00054

14. Rossi G.P., Bisogni V., Rossitto G. et al. Practice Recommendations for Diagnosis and Treatment of the Most Common Forms of Secondary Hypertension. High Blood Press Cardiovasc Prev. 2020;27(6):547-560. doi: 10.1007/s40292-020-00415-9

15. Pedrosa R.P., Drager L.F., Gonzaga C.C. et al. Obstructive sleep apnea: the most common secondary cause of hypertension associated with resistant hypertension. Hypertension. 2011 Nov;58(5):811-7. doi: 10.1161/HYPERTENSIONAHA.111.179788

16. Grossman E., Messerli F.H. Drug-induced hypertension: an unappreciated cause of secondary hypertension. Am J Med. 2012 Jan;125(1):14-22. doi: 10.1016/j.amjmed.2011.05.024

17. Ettehad D., Emdin C.A., Kiran A. et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016 Mar 5;387(10022):957-967. doi: 10.1016/S0140-6736(15)01225-8. Epub 2015 Dec 24.

18. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 7. Effects of more vs. less intensive blood pressure lowering and different achieved blood pressure levels - updated overview and meta-analyses of randomized trials. J Hypertens. 2016 Apr;34(4):613-22. doi: 10.1097/HJH.0000000000000881

19. Sundström J., Arima H., Jackson R. et al. Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of blood pressure reduction in mild hypertension: a systematic review and meta-analysis. Ann Intern Med. 2015 Feb 3;162(3):184-91. doi: 10.7326/M14-0773

20. Zanchetti A., Grassi G., Mancia G. When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisal. J Hypertens. 2009 May;27(5):923-34. doi: 10.1097/HJH.0b013e32832aa6b5

21. Arguedas J.A., Leiva V., Wright J.M. Blood pressure targets in adults with hypertension. Cochrane Database Syst Rev. 2020 Dec 17;12(12):CD004349. doi: 10.1002/14651858.CD004349.pub3

22. Unger T., Borghi C., Charchar F. et al. 2020 International Society of Hypertension global hypertension practice guidelines. J Hypertens. 2020 Jun;38(6):982-1004. doi: 10.1097/HJH.0000000000002453

23. Chen T., Shao F., Chen K. et al. Time to Clinical Benefit of Intensive Blood Pressure Lowering in Patients 60 Years and Older With Hypertension: A Secondary Analysis of Randomized Clinical Trials. JAMA Intern Med. 2022 Jun 1;182(6):660-667. doi: 10.1001/jamainternmed.2022.1657. Erratum in: JAMA Intern Med. 2022 Jul 5;:null.

24. Odden M.C., McClure L.A., Sawaya B.P. et al. Achieved Blood Pressure and Outcomes in the Secondary Prevention of Small Subcortical Strokes Trial. Hypertension. 2016 Jan;67(1):63-9. doi: 10.1161/HYPERTENSIONAHA.115.06480. Epub 2015 Nov 9. PMID: 26553236

25. Qaseem A., Wilt T.J., Rich R. et al. Clinical Guidelines Committee of the American College of Physicians and the Commission on Health of the Public and Science of the American Academy of Family Physicians. Pharmacologic Treatment of Hypertension in Adults Aged 60 Years or Older to Higher Versus Lower Blood Pressure Targets: A Clinical Practice Guideline From the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med. 2017 Mar 21;166(6):430- 437. doi: 10.7326/M16-1785. Epub 2017 Jan 17. Erratum in: Ann Intern Med. 2018 Apr 3;168(7):530-532.

26. Garrison S.R., Kolber M.R., Korownyk C.S. et al. Blood pressure targets for hypertension in older adults. Cochrane Database Syst Rev. 2017 Aug 8;8(8):CD011575. doi: 10.1002/14651858.CD011575.pub2

27. Guidelines on treatment of patients with arterial hypertension comorbid with metabolic disorders and diabetes mellitus type 2. Systemic Hypertension. 2020;17(1):7–45. (in Russ). doi: 10.26442/2075082X.2020.1.200051

28. Brunström M., Carlberg B. Association of Blood Pressure Lowering With Mortality and Cardiovascular Disease Across Blood Pressure Levels: A Systematic Review and Meta-analysis. JAMA Intern Med. 2018 Jan 1;178(1):28-36. doi: 10.1001/jamainternmed.2017.6015

29. MacDonald T.M., Williams B., Webb D.J. et al. British Hypertension Society Programme of Prevention And Treatment of Hypertension With Algorithm-based Therapy (PATHWAY). Combination Therapy Is Superior to Sequential Monotherapy for the Initial Treatment of Hypertension: A Double-Blind Randomized Controlled Trial. J Am Heart Assoc. 2017 Nov 18;6(11):e006986. doi: 10.1161/JAHA.117.006986

30. Williams B., MacDonald T.M., Morant S.V. et al. British Hypertension Society programme of Prevention And Treatment of Hypertension With Algorithm based Therapy (PATHWAY) Study Group. Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies. Lancet Diabetes Endocrinol 2018;6(6):464-475. doi: 10.1016/S2213-8587(18)30071-8

31. Wald D.S., Law M., Morris J.K. et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med. 2009 Mar;122(3):290-300. doi: 10.1016/j.amjmed.2008.09.038

32. Dahlöf B., Sever P.S., Poulter N.R. et al. ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005 Sep 10-16;366(9489):895- 906. doi: 10.1016/S0140-6736(05)67185-1

33. Gupta A.K., Arshad S., Poulter N.R. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a metaanalysis. Hypertension. 2010 Feb;55(2):399-407. doi: 10.1161/HYPERTENSIONAHA.109.139816

34. Volpe M., Christian Rump L., Ammentorp B., Laeis P. Efficacy and safety of triple antihypertensive therapy with the olmesartan/amlodipine/ hydrochlorothiazide combination. Clin Drug Investig. 2012 Oct 1;32(10):649-64. doi: 10.1007/BF03261919

35. Liu L., Xu B., Ju Y. Addition of spironolactone in patients with resistant hypertension: A meta-analysis of randomized controlled trials. Clin Exp Hypertens. 2017;39(3):257-263. doi: 10.1080/10641963.2016.

36. ONTARGET Investigators, Yusuf S., Teo K.K., et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. The New England Journal of Medicine. 2008 Apr;358(15):1547-1559. doi: 10.1056/nejmoa0801317

37. Catapano A.L., Graham I., De Backer G. et al. ESC Scientific Document Group. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J. 2016 Oct 14;37(39):2999-3058. doi: 10.1093/eurheartj/ehw272

38. Ezhov M.V., Sergienko I.V., Aronov D.M. et al. Diagnosis and correction of lipid metabolism disorders in order to prevent and treat atherosclerosis. Russian recommendations VI revision. Atherosclerosis and dyslipidemia. 2017;3(28):5–22. (in Russ).

39. Inzucchi S.E., Bergenstal R.M., Buse J.B. et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2012 Jun;55(6):1577-96. doi: 10.1007/s00125-012-2534-0

40. van den Born B.H., Lip G.Y.H., Brguljan-Hitij J. et al. ESC Council on hypertension position document on the management of hypertensive emergencies. Eur Heart J Cardiovasc Pharmacother. 2019 Jan 1;5(1):37- 46. doi: 10.1093/ehjcvp/pvy032

41. Vaughan C.J., Delanty N. Hypertensive emergencies. Lancet. 2000 Jul 29;356(9227):411-7. doi: 10.1016/S0140-6736(00)02539-3

42. Kutyrina I.M., Shvetsov M.YU., Fomin V.V. et al. Clinical guidelines. Diagnosis and treatment of arterial hypertension in chronic kidney disease. Klinicheskaya nefrologiya. 2015;(4):4-29 (In Russ.).

43. Ridao N., Luño J., García de Vinuesa S. et al. Prevalence of hypertension in renal disease. Nephrol Dial Transplant. 2001;16 Suppl 1:70-73. http://www.ncbi.nlm.nih.gov/pubmed/18457801

44. Boesen E.I., Kakalij R.M. Autoimmune-Mediated Renal Disease and Hypertension. Vol 135.; 2021:2165-2196. doi: 10.1042/CS20200955

45. Kutyrina I.M., Martynov S.A., Shvetsov M.YU. Arterial hypertension in chronic glomerulonephritis: detection rate and treatment efficacy. Terapevticheskii arkhiv. 2004;(9):10-15 (In Russ.).

46. Kidney Disease Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2013;Suppl (3 (1)):1- 150. doi: 10.1038/ki.2013.243

47. Moiseev V.S., Mukhin N.A., ed. National guideline. Cardiovascular risk and chronic kidney disease: strategies for cardionephroprotection.. Klinicheskaya nefrologiya. 2014;(2):4-29 (In Russ.).

48. Shilov E.M., Smirnov A.V., Kozlovskaya N.L., ed. Nephrology. Clinical guidelines. GEHOTAR-Media; 2016 (In Russ.).

49. Weiner D.E., Tighiouart H., Elsayed E.F. et al. The Framingham predictive instrument in chronic kidney disease. J Am Coll Cardiol. 2007;50(3):217- 224. doi: 10.1016/j.jacc.2007.03.037

50. Martynov S.A., Shvetsov M.YU., Kutyrina I.M. Blood pressure circadian rhythm disorders in patients with chronic glomerulonephritis. Terapevticheskii arkhiv. 2006;(1):23-27 (In Russ.).

51. Rahman M., Wang X., Bundy J.D. et al. Prognostic Significance of Ambulatory BP Monitoring in CKD: A Report from the Chronic Renal Insufficiency Cohort (CRIC) Study. J Am Soc Nephrol. 2020;31(11):2609- 2621. doi: 10.1681/ASN.2020030236

52. Chen T.K., Knicely D.H., Grams M.E. Chronic Kidney Disease Diagnosis and Management: A Review. JAMA. 2019;322(13):1294-1304. doi: 10.1001/JAMA.2019.14745

53. Sarafidis P.A., Persu A., Agarwal R. et al. Hypertension in dialysis patients: a consensus document by the European Renal and Cardiovascular Medicine (EURECA-m) working group of the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) and the Hypertension and the Kidney. Nephrol Dial Transplant. 2017;32(4):620-640. doi: 10.1093/NDT/GFW433

54. Lv J., Ehteshami P., Sarnak M.J. et al. Effects of intensive blood pressure lowering on the progression of chronic kidney disease: a systematic review and meta-analysis. CMAJ. 2013;185(11):949-957. doi: 10.1503/cmaj.121468

55. KDIGO Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int. 2012;2(5):337-414.

56. SPRINT Research Group, Wright J.T., Williamson J.D., et al. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 2015;373(22):2103-2116. doi: 10.1056/NEJMoa1511939

57. Whelton P.K., Carey R.M., Aronow W.S. et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults a report of the American College of Cardiology/American Heart Association Task Force on Clinical pr. Hypertension. 2018;71(6):E13-E115. doi: 10.1161/HYP.0000000000000065/-/DC2

58. Cheung A.K., Chang T.I., Cushman W.C. et al. KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int. 2021;99(3S):S1-S87. doi: 10.1016/J.KINT.2020.11.003

59. National Kidney Foundation. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis. 2004;43(1-290)

60. Jafar T.H., Stark P.C., Schmid C.H. et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensinconverting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med. 2003;139(4):244-252. http://www.ncbi.nlm.nih.gov/pubmed/12965979

61. Cobb M., Pacitti D. The Importance of Sodium Restrictions in Chronic Kidney Disease. J Ren Nutr. 2018;28(5):e37-e40. doi: 10.1053/j.jrn.2018.02.001

62. Cibulka R., Racek J. Metabolic disorders in patients with chronic kidney failure. Physiol Res. 2007;56(6):697-705. doi: 10.33549/PHSIOLRES.931128

63. Lee S., Kang S., Joo Y.S. et al. Smoking, Smoking Cessation, and Progression of Chronic Kidney Disease: Results From KNOW-CKD Study. Nicotine Tob Res. 2021;23(1):92-98. doi: 10.1093/NTR/NTAA071

64. Li Y., Zhu B., Song N. et al. Alcohol consumption and its association with chronic kidney disease: Evidence from a 12-year China health and Nutrition Survey. Nutr Metab Cardiovasc Dis. 2022;32(6):1392-1401. doi: 10.1016/J.NUMECD.2022.02.012

65. Lotan Y., Daudon M., Bruyère F. et al. Impact of fluid intake in the prevention of urinary system diseases: a brief review. Curr Opin Nephrol Hypertens. 2013;22 Suppl 1(Suppl 1):S1-10. doi: 10.1097/MNH.0b013e328360a268

66. Sontrop J.M., Dixon S.N., Garg A.X. et al. Association between water intake, chronic kidney disease, and cardiovascular disease: a crosssectional analysis of NHANES data. Am J Nephrol. 2013;37(5):434-442. doi: 10.1159/000350377

67. Wagner S., Merkling T., Metzger M., et al. Water intake and progression of chronic kidney disease: the CKD-REIN cohort study. Nephrol Dial Transplant. 2022;37(4):730-739. doi: 10.1093/NDT/GFAB036

68. Ikizler T.A., Burrowes J.D., Byham-Gray L.D., et al. KDOQI Clinical Practice Guideline for Nutrition in CKD: 2020 Update. Am J Kidney Dis. 2020;76(3):S1-S107. doi: 10.1053/J.AJKD.2020.05.006

69. Ruggenenti P., Perna A., Gherardi G., et al. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Lancet. 1998;352:1252-1256.

70. Brenner B.M., Cooper M.E., de Zeeuw D., et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861-869. doi: 10.1056/NEJMOA011161

71. Vogt L., Waanders F., Boomsma F. et al. Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan. J Am Soc Nephrol. 2008;19(5):999-1007. doi: 10.1681/ASN.2007060693

72. Bakris G.L., Sarafidis P.A., Weir M.R., et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet. 2010;375(9721):1173- 1181. doi: 10.1016/S0140-6736(09)62100-0

73. Ohno S., Ishii A., Yanagita M. et al. Calcium channel blocker in patients with chronic kidney disease. Clin Exp Nephrol. 2022;26(3):207-215. doi: 10.1007/S10157-021-02153-1

74. Fried L.F., Emanuele N., Zhang J.H., et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med. 2013;369(20):1892-1903. doi: 10.1056/NEJMoa1303154

75. Maione A., Navaneethan S.D., Graziano G., et al. Angiotensinconverting enzyme inhibitors, angiotensin receptor blockers and combined therapy in patients with micro- and macroalbuminuria and other cardiovascular risk factors: a systematic review of randomized controlled trials. Nephrol Dial Transplant. 2011;26(9):2827-2847. doi: 10.1093/ndt/gfq792

76. Dickinson H.O., Mason J.M., Nicolson D.J., et al. Lifestyle interventions to reduce raised blood pressure: a systematic review of randomized controlled trials. J Hypertens. 2006;24(2):215-233. doi: 10.1097/01.hjh.0000199800.72563.26

77. Pokrovskij А.V., Bogatov YU.P. Vasorenal hypertension. Ch. in the book: Arterial hypertension guidance. Ed. E.I. Chazova, I.E. Chazovoi. Moscow: MediaMedica, 2005; 95-117 (in Russ.).

78. Shilov E.M., Batyushkin M.M. Renovascular hypertension and ischemic kidney disease. In: Nephrology. Clinical guidelines. Ed. E.M. Shilova, A.V. Smirnova, N.L. Kozlovskaya. M.: GEOTAR-Media, 2016; 449-460 (in Russ).

79. Mukhin N.А., Fomin V.V. Atherosclerotic stenosis of the renal arteries. In: Guide to atherosclerosis and coronary heart disease. Ed. E.I. Chazov, V.V. Kukharchuk, S.A. Boytsov. Media Medica, 2007; 248-273 (in Russ).

80. Herrmann S.M., Textor S.C. Renovascular Hypertension. Endocrinol Metab Clin North Am. 2019 Dec;48(4):765-778. doi: 10.1016/j.ecl.2019.08.007

81. de Mast Q., Beutler J.J. The prevalence of atherosclerotic renal artery stenosis in risk groups: a systematic literature review. J Hypertens. 2009 Jul;27(7):1333-40. doi: 10.1097/HJH.0b013e328329bbf4

82. Boutari C., Georgianou E., Sachinidis A. et al. Renovascular Hypertension: Novel Insights. Curr Hypertens Rev. 2020;16(1):24-29. doi: 10.2174/1573402115666190416153321

83. Mousa A.Y., Campbell J.E., Stone P.A. et al. Short- and long-term outcomes of percutaneous transluminal angioplasty/stenting of renal fibromuscular dysplasia over a ten-year period. J Vasc Surg. 2012 Feb;55(2):421-7. doi: 10.1016/j.jvs.2011.09.006

84. Tafur-Soto J.D., White C.J. Renal artery stenosis. Cardiology Clinics 2015; 33(1):59–73. doi: 10.1016/j.ccl.2014.09.006

85. Fomin V.V., Kutyrina I.M., Shvetsov M.Yu. Ischemic kidney disease. In the book: Nephrology. National leadership. Сoncise edition. Ch. ed. N.A Mukhin. - M.: «GEOTAR-Media», 2014. - C. 377-386 (in Russ).

86. Jennings C.G., Houston J.G., Severn A. et al. Renal artery stenosis-when to screen, what to stent? Curr Atheroscler Rep. 2014 Jun;16(6):416. doi: 10.1007/s11883-014-0416-2.

87. Aboyans V., Ricco J.B., Bartelink M.E.L. et al. ESC Scientific Document Group. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed by: the European Stroke Organization (ESO) The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J. 2018 Mar 1;39(9):763- 816. doi: 10.1093/eurheartj/ehx095

88. AbuRahma A.F., Yacoub M. Renal imaging: duplex ultrasound, computed tomography angiography, magnetic resonance angiography, and angiography. Semin Vasc Surg. 2013 Dec;26(4):134-43. doi: 10.1053/j.semvascsurg.2014.06.001

89. Chi Y.W., White C.J., Thornton S. et al. Ultrasound velocity criteria for renal in-stent restenosis. J Vasc Surg. 2009 Jul;50(1):119-23. doi: 10.1016/j.jvs.2008.12.066

90. Schäberle W., Leyerer L., Schierling W. et al. Ultrasound diagnostics of renal artery stenosis. Gefässchirurgie. 2016; 1(21):4–13. doi: 10.1007/s00772-015-0060-3

91. Fananapazir G., McGahan J.P., Corwin M.T. et al. Screening for Transplant Renal Artery Stenosis: Ultrasound-Based Stenosis Probability Stratification. AJR Am J Roentgenol. 2017 Nov;209(5):1064-1073. doi: 10.2214/AJR.17.17913

92. Tan K.T., van Beek E.J., Brown P.W. et al. Magnetic resonance angiography for the diagnosis of renal artery stenosis: a meta-analysis. Clin Radiol. 2002 Jul;57(7):617-24. doi: 10.1053/crad.2002.0941

93. Bley T., Francois C., Schiebler M. Non-contrast-enhanced MRA of renal artery stenosis: validation against DSA in a porcine model. European Radiology 2016;26(2):547–55. doi: 10.1007/s00330-015-3833-x

94. Weber-Mzell D. Coronary anatomy predicts presence or absence of renal artery stenosis. A prospective study in patients undergoing cardiac catheterization for suspected coronary artery disease. European Heart Journal, 2002;23(21):1684–1691. doi: 10.1053/euhj.2002.3314

95. Kim D., Porter D. H., Brown R. et al. Renal Artery Imaging: A Prospective Comparison of Intra-Arterial Digital Subtraction Angiography with Conventional Angiography. Angiology.1991;42(5):345–357. doi: 10.1177/000331979104200501

96. Safian R.D. Renal artery stenosis. Prog Cardiovasc Dis. 2021 MarApr;65:60-70. doi: 10.1016/j.pcad.2021.03.003

97. Klein A.J., Jaff M.R., Gray B.H. et al. SCAI appropriate use criteria for peripheral arterial interventions: An update. Catheter Cardiovasc Interv. 2017 Oct 1;90(4):E90-E110. doi: 10.1002/ccd.27141

98. Balafa O., Kalaitzidis R., Siamopoulos K.C. Optimal medical management in patients with renovascular hypertension. Am J Cardiovasc Drugs. 2013 Apr;13(2):71-8. doi: 10.1007/s40256-013-0011-x

99. Hackam D.G., Spence J.D., Garg A.X. et al. Role of renin-angiotensin system blockade in atherosclerotic renal artery stenosis and renovascular hypertension. Hypertension. 2007 Dec;50(6):998-1003. doi: 10.1161/HYPERTENSIONAHA.107.097345

100. Manaktala R., Tafur-Soto J.D., White C.J. Renal Artery Stenosis in the Patient with Hypertension: Prevalence, Impact and Management. Integr Blood Press Control. 2020 Jun 2;13:71-82. doi: 10.2147/IBPC.S248579.

101. Evans K.L., Tuttle K.R., Folt D.A. et al. Use of renin-angiotensin inhibitors in people with renal artery stenosis. Clin J Am Soc Nephrol. 2014 Jul;9(7):1199-206. doi: 10.2215/CJN.11611113

102. Chrysochou C., Foley R.N., Young J.F. et al. Dispelling the myth: the use of renin-angiotensin blockade in atheromatous renovascular disease. Nephrol Dial Transplant. 2012 Apr;27(4):1403-9. doi: 10.1093/ndt/gfr496

103. Chen Y., Pan H., Luo G. et al. Use of percutaneous transluminal renal angioplasty in atherosclerotic renal artery stenosis: a systematic review and meta-analysis. J Int Med Res. 2021 Jan;49(1):300060520983585. doi: 10.1177/0300060520983585

104. Parikh S.A., Shishehbor M.H., Gray B.H. et al. SCAI expert consensus statement for renal artery stenting appropriate use. Catheter Cardiovasc Interv. 2014 Dec 1;84(7):1163-71. doi: 10.1002/ccd.25559

105. Mangiacapra F., Trana C., Sarno G. et al. Translesional pressure gradients to predict blood pressure response after renal artery stenting in patients with renovascular hypertension. Circ Cardiovasc Interv. 2010 Dec;3(6):537-42. doi: 10.1161/CIRCINTERVENTIONS.110.957704

106. Zeller T., Müller C., Frank U. et al. Stent angioplasty of severe atherosclerotic ostial renal artery stenosis in patients with diabetes mellitus and nephrosclerosis. Catheter Cardiovasc Interv. 2003 Apr;58(4):510-5. doi: 10.1002/ccd.10435

107. Mitchell J.A., Subramanian R., White C.J. et al. Predicting blood pressure improvement in hypertensive patients after renal artery stent placement: renal fractional flow reserve. Catheter Cardiovasc Interv. 2007 Apr 1;69(5):685-9. doi: 10.1002/ccd.21095

108. Trinquart L., Mounier-Vehier C., Sapoval M. et al. Efficacy of revascularization for renal artery stenosis caused by fibromuscular dysplasia: a systematic review and meta-analysis. Hypertension. 2010 Sep;56(3):525-32. doi: 10.1161/HYPERTENSIONAHA.110.152918. Epub 2010 Jul 12.

109. Steuer J., Bergqvist D., Björck M. Surgical Renovascular Reconstruction for Renal Artery Stenosis and Aneurysm: Long-Term Durability and Survival. European Journal of Vascular and Endovascular Surgery. 2018; 57(4):562-568. doi: 10.1016/j.ejvs.2018.09.014

110. Zotikov A.E., Beloyartsev D.F. Surgery for lesions of the renal arteries. Ch. in book. Surgery of the renal vessels. Ed. Revishvili A.Sh., Pokrovsky A.V., Zotikova A.E. Moscow: Russian Knights Foundation, 2021; 36-48 (in Russ).

111. Conlon P.J., Little M.A., Pieper K. et al. Severity of renal vascular disease predicts mortality in patients undergoing coronary angiography. Kidney Int. 2001 Oct;60(4):1490-7. doi: 10.1046/j.1523-1755.2001.00953.x

112. Young W.F. Primary aldosteronism: renaissance of a syndrome. Clin Endocrinol (Oxf). 2007;66(5):607-18. doi: 10.1111/j.1365-2265.2007.02775.x

113. Funder J.W., Carey R.M., Mantero F. et al. The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016;101(5):1889-1916. doi: 10.1210/jc.2015-4061

114. Rossi G.P., Bisogni V., Bacca A.V. et al. The 2020 Italian Society of Arterial Hypertension (SIIA) practical guidelines for the management of primary aldosteronism. Int J Cardiol Hypertens. 2020;5. doi: 10.1016/j.ijchy.2020.100029

115. Mulatero P., Stowasser M., Loh K.C. et al. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab. 2004;89:1045-50. doi: 10.1210/jc.2003-031337

116. Meng Z., Zhou L., Dai Z. et al. The Quality of Clinical Practice Guidelines and Consensuses on the Management of Primary Aldosteronism: A Critical Appraisal. Front Med (Lausanne). 2020;7:136. doi: 10.3389/fmed.2020.00136

117. Young W.F. Jr. Diagnosis and treatment of primary aldosteronism: practical clinical perspectives. J Intern Med. 2019;285(2):126-148. doi: 10.1111/joim.12831

118. Mulatero P., Monticone S., Deinum J. et al. Genetics, prevalence, screening and confirmation of primary aldosteronism: a position statement and consensus of the Working Group on Endocrine Hypertension of The European Society of Hypertension. J Hypertens. 2020 Oct;38(10):1919- 1928. doi: 10.1097/HJH.0000000000002510.

119. Mosso L., Carvajal C., González A. et al. Primary aldosteronism and hypertensive disease. Hypertension. 2003;42(2):161-5. doi: 10.1161/01.HYP.0000079505.25750.11

120. Douma S., Petidis K., Doumas M. et al. Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. Lancet. 2008 Jun 7;371(9628):1921-6. doi: 10.1016/S0140-6736(08)60834-X. Erratum in: Lancet. 2008 Dec 13;372(9655):2022.

121. Schmiemann G., Gebhardt K., Hummers-Pradier E. et al. Prevalence of hyperaldosteronism in primary care patients with resistant hypertension. J Am Board Fam Med. 2012;25:98-103. doi: 10.3122/jabfm.2012.01.110099

122. Chikhladze N.M. Primary hyperaldosteronism as a possible cause of resistant arterial hypertension. Systemic Hypertension. 2020; 17 (4): 20–23. (In Russ.) doi: 10.26442/2075082X.2020.4.200338

123. Rossi G.P., Bernini G., Caliumi C. et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol. 2006;48(11):2293-300. doi:10.1016/j.jacc.2006.07.059

124. Woo K., Waisman J., Melamed J. et al. Primary aldosteronism caused by unilateral adrenal hyperplasia. Rev Urol. 2000 Spring;2(2):100-4.

125. Goh B.K., Tan Y.H., Chang K.T. et al. Primary hyperaldosteronism secondary to unilateral adrenal hyperplasia: an unusual cause of surgically correctable hypertension. A review of 30 cases. World J Surg. 2007;31(1):72-79. doi: 10.1007/s00268-005-0594-8

126. Zennaro M.C., Jeunemaitre X. SFE/SFHTA/AFCE consensus on primary aldosteronism, part 5: Genetic diagnosis of primary aldosteronism. Ann Endocrinol (Paris). 2016;77(3):214-9. doi: 10.1016/ando.2016.02.00

127. Shkhvatsabaia IK, Chihladze NM. Giperal’dosteronizm i arterial’naia gipertoniia. Moscow: Meditsina, 1984 (in Russian).

128. Baguet J.P., Steichen O., Mounier-Véhier C. et al. SFE/SFHTA/ AFCE consensus on primary aldosteronism, part 1: Epidemiology of PA, who should be screened for sporadic PA? Ann Endocrinol (Paris). 2016;77(3):187-91. doi: 10.1016/j.ando.2016.01.006

129. Amar L., Plouin P.F., Steichen O. Aldosterone-producing adenoma and other surgically correctable forms of primary aldosteronism. Orphanet J Rare Dis. 2010;5:9. doi: 10.1186/1750-1172-5-9

130. Chikhladze N.M. The nature of the course of arterial hypertension in low-renin hyperaldosteronism. Systemic Hypertension. 2019; 16 (4): 22–26 (In Russ). doi: 10.26442/2075082X.2019.4.190574

131. Brown J.M., Robinson-Cohen C., Luque-Fernandez M.A. et al. The Spectrum of Subclinical Primary Aldosteronism and Incident Hypertension: A Cohort Study. Ann Intern Med. 2017;167(9):630-641. doi: 10.7326/M17-0882

132. Monticone S., D’Ascenzo F., Moretti C. et al. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2018;6(1):41-50. doi: 10.1016/S2213-8587(17)30319-4

133. Pan C.T., Tsai C.H., Chen Z.W. et al. Atrial Fibrillation in Primary Aldosteronism. Horm Metab Res. 2020;52(6):357-365. doi: 10.1055/a1141-5989

134. Chikhladze N.M. Primary hyperaldosteronism: indications for screening. Terapevticheskii Arkhiv. 2022;94(1):107–113 (In Russ). doi: 10.26442/00403660.2022.01.201324

135. Monticone S., Burrello J., Tizzani D. et al. Prevalence and Clinical Manifestations of Primary Aldosteronism Encountered in Primary Care Practice. J Am Coll Cardiol. 2017;69(14):1811-20. doi: 10.1016/j.jacc.2017.01.052

136. Ganguly A., Dowdy A.J., Luetscher J.A. et al. Anomalous postural response of plasma aldosterone concentration in patients with aldosteroneproducing adrenal adenoma. J Clin Endocrinol Metab. 1973. Vol. 36. N 2.P. 401-4.

137. Teresa Fuss C., Brohm K., Fassnacht M. et al. Reassessment of Postural Stimulation Testing as a Simple Tool to Identify a Subgroup of Patients With Unilateral Primary Aldosteronism. J Clin Endocrinol Metab. 2022 Jan 18;107(2):e865-e873. doi: 10.1210/clinem/dgab611

138. Mulatero P., Sechi L.A., Williams T.A. et al. Subtype diagnosis, treatment, complications and outcomes of primary aldosteronism and future direction of research: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension. J Hypertens. 2020;38(10):1929-1936. doi: 10.1097/HJH.0000000000002520

139. Williams T.A., Lenders J.W.M., Mulatero P. et al. Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. Lancet Diabetes Endocrinol. 2017;5(9):689-699. doi: 10.1016/S2213-8587(17)30135-3

140. Karagiannis A., Tziomalos K., Kakafika A.I. et al. Medical treatment as an alternative to adrenalectomy in patients with aldosterone-producing adenomas. Endocr Relat Cancer. 2008;15(3):693-700. doi: 10.1677/ERC-08-0094

141. Sechi L.A., Colussi G.L., Novello M. et al. Mineralocorticoid Receptor Antagonists and Clinical Outcomes in Primary Aldosteronism: As Good as Surgery? Horm Metab Res. 2015;47(13):1000-1006. doi: 10.1055/s0035-1565128

142. Chikladze N.M., Favorova O.O., Chazova I.E. Family hyperaldosteronism type I: a clinical case and review of literature. Terapevticheskii Arkhiv. 2018;90(9):115-22 (in Russ). doi: 10.26442/terarkh2018909115-122

143. Melnichenko G.A., Dedov I.I., Belaya J.E. еt аl. Russian federal clinical guidelines for Cushing’s disease. clinic, diagnostics, differential diagnostics, methods of treatment Problems of endocrinology 2015; 61(2):55-77 (In Russ). doi: 10.14341/proderalbl201561255-77

144. Nieman L.K., Biller B.M.K., Findling J.W. et al. The diagnosis of Cushing’s syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2008;93(5):1526-1540. doi: 10.1210/jc.2008-0125.

145. Feelders R., Sharma S., Nieman L. Cushing’s syndrome: epidemiology and developments in disease management. CLEP 2015: 281. doi: 10.2147/CLEP.S44336

146. Marova E.I., Belaya J.E. Malyigina A.A. et al. Itsenko-Cushing’s disease (textbook). - M.: FGBU «NMITs Endocrinology» of the Ministry of Health of Russia (In Russ).

147. Lindholm J., Juul S., Jørgensen J.O.L. et al. Incidence and Late Prognosis of Cushing’s Syndrome: A Population-Based Study 1. The Journal of Clinical Endocrinology & Metabolism 2001;86(1):117–123. doi: 10.1210/jcem.86.1.7093

148. Etxabe J., Vazquez J.A. Morbidity and mortality in Cushing’s disease: an epidemiological approach. Clin Endocrinol 1994;40(4):479–484. doi: 10.1111/j.1365-2265.1994.tb02486.x

149. Broder M.S., Neary M.P., Chang E. et al. Incidence of Cushing’s syndrome and Cushing’s disease in commercially-insured patients < 65 years old in the United States. Pituitary 2015;18(3):283–289. doi: 10.1007/s11102-014-0569-6

150. Trifanescu R., Carsote M., Caragheorgheopol A. et al. Screening for secondary endocrine hypertension in young patients. Maedica (Bucur). 2013;8(2):108–115.

151. Omura M., Saito J., Yamaguchi K. et al. Prospective study on the prevalence of secondary hypertension among hypertensive patients visiting a general outpatient clinic in Japan. Hypertens Res. 2004;27(3):193–202. doi: 10.1291/hypres.27.193

152. Belaya J.E., Rozhinskaya L.Y., Dragunova N.V. et al. Metabolic complications of endogenous hypercortisolism. Selection of patients for screening. Obesity and Metabolism. – 2013(1). – 29–34 (in Russ.).

153. Valassi E., Santos A., Yaneva M. et al. ERCUSYN Study Group. The European Registry on Cushing’s syndrome: 2-year experience. Baseline demographic and clinical characteristics. Eur J Endocrinol. 2011 Sep;165(3):383-92. doi: 10.1530/EJE-11-0272

154. Dedov I.I., Mellnichenko G.A. Endocrinology. National Guide. 2nd ed. — M.: GEOTAR-Media; 2018 (In Russ).

155. Belaya J.E., Malyigina A.A., Grebennikova T.A., Iljin A.V. et al. Diagnostic possibilities salivary cortisol during a night test with 1 mg dexamethasone. Obesity and metabolism. 2020;17(1):13-21 (In Russ). doi: 10.14341/omet10117

156. Belaya J.E., Iljin A.V. Melnichenko G.A. et al. Automatic electrochemiluminescent method for the determination of cortisol in saliva for the diagnosis of endogenous hypercortisolism among obese patients.Obesity and metabolism. 2011;27(2):56-63 (In Russ).

157. Sereg M., Tőke J., Patócs A. et al. Diagnostic performance of salivary cortisol and serum osteocalcin measurements in patients with overt and subclinical Cushing’s syndrome. Steroids 2011;76(1–2):38–42. doi: 10.1016/j.steroids.2010.08.007

158. Hong A.R., Kim J.H., Hong E.S. et al Limited Diagnostic Utility of Plasma Adrenocorticotropic Hormone for Differentiation between Adrenal Cushing Syndrome and Cushing Disease. Endocrinol Metab 2015;30(3):297. doi: 10.3803/EnM.2015.30.3.297

159. Liu Z., Zhang X., Wang Z. et al. High positive predictive value of the combined pituitary dynamic enhanced MRI and high-dose dexamethasone suppression tests in the diagnosis of Cushing’s disease bypassing bilateral inferior petrosal sinus sampling. Sci Rep 2020;10(1):14694. doi: 10.1038/s41598-020-71628-0

160. Pinelli S., Barbot M., Scaroni C. et al. Second-Line Tests in the Diagnosis of Adrenocorticotropic Hormone-Dependent Hypercortisolism. Ann Lab Med 2021;41(6):521–531. doi: 10.3343/alm.2021.41.6.521

161. Colao A., Petersenn S., Newell-Price J. et al. A 12-Month Phase 3 Study of Pasireotide in Cushing’s Disease. N Engl J Med.2012;366(10):914–924. doi: 10.1056/NEJMoa1105743

162. Barbot M., Ceccato F., Scaroni C. The Pathophysiology and Treatment of Hypertension in Patients With Cushing’s Syndrome. Front Endocrinol (Lausanne). 2019 May 21;10:321. doi: 10.3389/fendo.2019.00321

163. Isidori A.M., Graziadio C., Paragliola R.M. et al, ABC Study Group. The hypertension of Cushing’s syndrome: controversies in the pathophysiology and focus on cardiovascular complications. J Hypertens. 2015 Jan;33(1):44-60. doi: 10.1097/HJH.0000000000000415

164. Cicala M.V., Mantero F. Hypertension in Cushing’s syndrome: from pathogenesis to treatment. Neuroendocrinology. 2010;92 Suppl 1:44-9. doi: 10.1159/000314315

165. Ritzel K., Beuschlein F., Mickisch A., Osswald A. et. al. Outcome of Bilateral Adrenalectomy in et alCushing’s Syndrome: A Systematic Review. The Journal of Clinical Endocrinology & Metabolism 2013; 98(10): 3939– 3948. doi: 10.1210/jc.2013-1470

166. Lenders J.W.M., Duh Q.-Y., Eisenhofer G. et al. Pheochromocytoma and paraganglioma: An endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(6):1915-1942. doi: 10.1210/jc.2014-1498

167. Lenders J.W.M., Kerstens M.N., Amar L., et al. Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension. J Hypertens. 2020;38(8):1443-1456. doi: 10.1097/HJH.0000000000002438

168. Calissendorff J., Juhlin C.C., Bancos I. et al. Pheochromocytomas and Abdominal Paragangliomas: A Practical Guidance. Cancers (Basel). 2022 Feb 12;14(4):917. doi: 10.3390/cancers14040917

169. Falhammar H., Kjellman M., Calissendorff J. Initial clinical presentation and spectrum of pheochromocytoma: a study of 94 cases from a single center. Endocr Connect. 2018;7(1):186-192. doi: 10.1530/EC-17-0321

170. Ebbehoj A., Stochholm K., Jacobsen S.F. et al. Incidence and Clinical Presentation of Pheochromocytoma and Sympathetic Paraganglioma: A Population-based Study. J. Clin. Endocrinol. Metab. 2021;106:e2251– e2261. doi: 10.1210/clinem/dgaa965

171. Mete O., Asa S.L., Gill A.J. et al. Overview of the 2022 WHO Classification of Paragangliomas and Pheochromocytomas. Endocr Pathol. 2022 Mar;33(1):90-114. doi: 10.1007/s12022-022-09704-6

172. Garcia-Carbonero R., Matute Teresa F., Mercader-Cidoncha E. et al. Multidisciplinary practice guidelines for the diagnosis, genetic counseling and treatment of pheochromocytomas and paragangliomas. Clin Transl Oncol. 2021 Oct;23(10):1995-2019. doi: 10.1007/s12094-021-02622-9

173. Fishbein L., Del Rivero J., Else T. et al. The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Management of Metastatic and/or Unresectable Pheochromocytoma and Paraganglioma. Pancreas. 2021;50(4):469-493. doi: 10.1097/MPA.0000000000001792

174. Zuber S.M., Kantorovich V., Pacak K. Hypertension in pheochromocytoma: characteristics and treatment. Endocrinol Metab Clin North Am. 2011 Jun;40(2):295-311, vii. doi: 10.1016/j.ecl.2011.02.002

175. Bravo E.L., Tagle R. Pheochromocytoma: state-of-the-art and future prospects. Endocr Rev. 2003;24(4):539-553. doi: 10.1210/er.2002-0013

176. Geroula A., Deutschbein T., Langton K. et al. (2019). Pheochromocytoma and paraganglioma: clinical feature-based disease probability in relation to catecholamine biochemistry and reason for disease suspicion. European Journal of Endocrinology, 181(4):409-420. doi: 10.1530/EJE-19-0159

177. Mokhort T.V., Velesevich E.I., Mokhort E.G. Pheochromocytoma: new approaches to diagnosis and management, Meditsinskie novosti. 2016;(4):3-10 (in Russ.).

178. Calhoun D.A., Jones D., Textor S. et al.; American Heart Association Professional Education Committee. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation. 2008 Jun 24;117(25):e510-26. doi: 10.1161/CIRCULATIONAHA.108.189141

179. Y-Hassan S., Falhammar H. Cardiovascular Manifestations and Complications of Pheochromocytomas and Paragangliomas. J Clin Med. 2020 Jul 30;9(8):2435. doi: 10.3390/jcm9082435

180. Bel’tsevich D.G., Troshina E.A., Iukina M.I. Pheochromocytoma. Problems of Endocrinology. 2010;56(1):63-71. (In Russ). doi: 10.14341/probl201056163-71

181. Zelinka T., Pacák K., Widimský J. Jr. Characteristics of blood pressure in pheochromocytoma. Ann N Y Acad Sci. 2006 Aug;1073:86-93. doi: 10.1196/annals.1353.009

182. Falhammar H., Kjellman M., Calissendorff J. Treatment and outcomes in pheochromocytomas and paragangliomas: a study of 110 cases from a single center. Endocrine. 2018;62(3):566-575. doi: 10.1007/s12020-018-1734-x

183. Mel’nichenko G.A., Troshina E.A., Bel’tsevich D.G., et al. Russian Association of Endocrinologists clinical practice guidelines for diagnosis and treatment of pheochromocytoma and paraganglioma. Endocrine Surgery. 2015;9(3):15-33 (In Russ.). doi: 10.14341/serg2015315-33

184. Antonio K., Valdez M.M.N., Mercado-Asis L., et al. Pheochromocytoma/ paraganglioma: recent updates in genetics, biochemistry, immunohistochemistry, metabolomics, imaging and therapeutic options. Gland Surg. 2020 Feb;9(1):105-123. doi: 10.21037/gs.2019.10.25

185. Iukina M.Iu., Troshina E.A., Bel’tsevich D.G. Hereditary pheochromocytoma-associated syndromes. Part 1. Terapevticheskii Arkhiv. 2015;87(9):102-105. (In Russ.). doi: 10.17116/terarkh2015879102-105

186. Plouin P.F., Amar L., Dekkers O.M., et al. Guideline Working Group European Society of Endocrinology Clinical Practice Guideline for longterm follow-up of patients operated on for a phaeochromocytoma or a paraganglioma. Eur. J. Endocrinol. 2016;174:G1–G10. doi: 10.1530/EJE16-0033

187. Weismann D., Liu D., Bergen T., et al. Hypertension and hypertensive cardiomyopathy in patients with a relapse-free history of phaeochromocytoma. Clin. Endocrinol. 2015;82(2):188–196. doi: 10.1111/cen.12536

188. Bahn R.S., Burch H.B., Cooper D.S. et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the american thyroid association and American association of clinical endocrinologists. Endocr. pract. 2011;17(3):456-520. doi: 10.4158/ep.17.3.456

189. Ross D.S., Burch H.B., Cooper D.S. et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016;26(10):1343-1421. doi: 10.1089/thy.2016.0229

190. Russian Association of Endocrinologists. National recommendations: Thyrotoxicosis with diffuse goiter (diffuse toxic goiter, Graves–Basedow disease), nodular/multinodular goiter. M.; 2014 (in Russ.).

191. William F. Young Jr., Calhoun D.A. et al. Screening for Endocrine Hypertension: An Endocrine Society Scientific Statement. Endocrine Reviews. 2017;3(2):103-122. doi: 10.1210/er.2017-00054

192. Selmer C., Olesen J.B., Hansen M.L. et al. Subclinical and overt thyroid dysfunction and risk of all-cause mortality and cardiovascular events: a large population study. J Clin Endocrinol Metab. 2014;99(7):2372-2382. doi: 10.1210/jc.2013-4184

193. Sohn S.Y., Lee E., Lee M.K. et al. The association of overt and subclinical hyperthyroidism with the risk of cardiovascular events and cardiovascular mortality: meta-analysis and systematic review of cohort studies. Endocrinol Metab (Seoul). 2020;35(4):786-800. doi: 10.3803/EnM.2020.728

194. Berta, E., Lengyel, I., Halmi, S. et al. Hypertension in Thyroid Disorders. Front. Endocrinol. 2019;10:482. doi: 10.3389/fendo.2019.00482

195. Kahaly G.J., Olivo P.D. Graves’ disease. N Engl J Med. 2017;376(2):184. doi: 10.1056/NEJMc1614624

196. Tozzoli R., Bagnasco M., Giavarina D. et al. TSH receptor autoantibody immunoassay in patients with Graves’ disease: improvement of diagnostic accuracy over different generations of methods: systematic review and meta-analysis. Autoimmun Rev. 2012;12(2):107–113. doi: 10.1016/j.autrev.2012.07.003

197. Kahaly G.J., Bartalena L., Hegedus L. The American Thyroid Association/ American Association of Clinical Endocrinologists guidelines for hyperthyroidism and other causes of thyrotoxicosis: a European perspective. Thyroid. 2011;21(6):585–591. doi: 10.1089/thy.2011.2106.ed3

198. Collet T.H., Gussekloo J., Bauer D.C. et al. Thyroid Studies Collaboration: Subclinical hyperthyroidism and the risk of coronary heart disease and mortality. Arch Intern Med. 2012;172(10):799–809. doi: 10.1001/archinternmed.2012.402

199. Bartalena L., Burch H.B., Burman K.D. et al. A 2013 European survey of clinical practice patterns in the management of Graves ‘disease. Clin Endocrinol. 2016;84(1):115–120. doi: 10.1111/cen.12688

200. Chazova I.E., Golitsyn S.P., Zhernakova Ju.V. et al. Management of patients with arterial hypertension and atrial fibrillation. Systemic Hypertension. 2021;18(3):105–128 (In Russ.). doi: 10.26442/2075082X.2021.3.201077

201. Corvilain B., Hamy A., Brunaud L. et al. Treatment of adult Graves’ disease. Ann Endocrinol (Paris) (2018). doi: 10.1016/j.ando.2018.08.003

202. Kahaly G.J., Bartalena L., Hegedüs L. et al. 2018 European Thyroid Association Guideline for the Management of Graves’ Hyperthyroidism. Eur Thyroid J. 2018;7:167–186. doi: 10.1159/000490384

203. Brito J.P., Schilz S., Singh Ospina N. et al. Antithyroid drugs – the most common treatment for Graves’ disease in the United States: a nationwide population-based study. Thyroid. 2016;26(8):1144–1145. doi: 10.1089/thy.2016.0222

204. Biondi B., Bartalena L., Cooper D.S. et al. The 2015 European Thyroid Association guidelines on diagnosis and treatment of endogenous subclinical hyperthyroidism. Eur Thyroid J. 2015;4(3):149–163. doi: 10.1159/000438750

205. Tagami T., Yambe Y., Tanaka T. et al. BBGD Study Group. Shortterm effects of beta-adrenergic antagonists and methimazole in new-onset thyrotoxicosis caused by Graves’ disease. Intern Med. 2012;51(17):2285– 2290. doi: 10.2169/internalmedicine.51.7302

206. Satoh T., Isozaki O., Suzuki A. et al. 2016 guidelines for the management of thyroid storm from the Japan Thyroid Association and Japan Endocrine Society (first edition). Endocr J. 2016;63:1025–1064. doi: 10.1507/endocrj.EJ16-0336

207. Isozaki O., Satoh T., Wakino S. et al. Treatment and management of thyroid storm: analysis of the nationwide surveys: the taskforce committee of the Japan Thyroid Association and Japan Endocrine Society for the establishment of diagnostic criteria and nationwide surveys for thyroid storm. Clin Endocrinol. 2016;84:912–918. doi: 10.1111/cen.12949

208. Meyerovitch J., Rotman-Pikielny P., Sherf M. et al. Serum thyrotropin measurements in the community: five-year follow-up in a large network of primary care physicians. Arch Intern Med. 2007;167(14):1533–8. doi: 10.1001/archinte.167.14.1533.

209. Persani L., Cangiano B., Bonorni M. The diagnosis and management of central hypothyroidism in 2018. Endocr Connect. 2019;8(2):44-54. doi: 10.1530/EC-18-0515

210. Mazza A., Beltramello G., Armigliato M. et al. Arterial hypertension and thyroid disorders: What is important to know in clinical practice? Ann Endocrinol. 2011;72:296–303. doi: 10.1016/j.ando.2011.05.004

211. Piantanida E., Gallo D., Veronesi G. et al. Masked hypertension in newly diagnosed hypothyroidism: a pilot study. J Endocrinol Invest. 2016;39(10):1131-1138. doi: 10.1007/s40618-016-0488-7.

212. Surks M.I., Ortiz E., Daniels G. et al. Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. Jama. 2004;291(2):228-238. doi: 10.1001/jama.291.2.228

213. Raber W., Gessl A., Nowotny P. et al. Thyroid ultrasound versus antithyroid peroxidase antibody determination: a cohort study of four hundred fifty-one subjects. Thyroid. 2002; 12(8):725-731. doi: 10.1089/105072502760258712

214. McAninch E.A., Rajan K.B., Miller C.H. et al. Systemic thyroid hormone status during levothyroxine therapy in hypothyroidism: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2018;103(12):4533- 4542. doi: 10.1210/jc.2018-01361

215. Jonklaas J., Bianco A.C., Bauer A.J. et al. Guidelines for the treatment of hypothyroidism: prepared by the American thyroid association task force on thyroid hormone replacement. Thyroid. 2014 Dec;24(12):1670-751. doi: 10.1089/thy.2014.0028

216. Pokrovskij A.V., Zotikov A.E., Yudin V.I. Nonspecific aortoarteritis (Takayasu’s disease). M.: IRIS, 2002 (in Russ.)

217. Arnaud L., Haroche J., Limal N. et al. Takayasu arteritis in France: a singlecenter retrospective study of 82 cases comparing white, North African, and black patients. Medicine (Baltimore). 2010;89(1):1-17. doi: 10.1097/MD.0b013e3181cba0a3

218. Saadoun D., Bura-Riviere A., Comarmond C. et al. French recommendations for the management of Takayasu’s arteritis. Orphanet J Rare Dis. 2021 Jul 21;16(Suppl 3):311. doi: 10.1186/s13023-021-01922-1

219. Mammeri A., Guermaz R., Hatri A. et al. L’hypertension artérielle au cours de la maladie de Takayasu: à propos d’une série monocentrique de 279 patients [Hypertension during Takayasu’s disease: An Algerian single center experience of 279 patients]. Ann Cardiol Angeiol (Paris). 2017;66(3):154-158. doi: 10.1016/j.ancard.2017.04.006

220. Chikhladze, N. M., Sivakova, O. A., Chazova, I. E. Clinical manifestations of damage of cardiovascular system in Takayasu arteritis Systemic Hypertension. 2008;5(4)22-24 (in Russ). doi: 10.26442/SG28828

221. Ham S.W., Kumar S.R., Rowe V.L. et al. Disease progression after initial surgical intervention for Takayasu arteritis. J Vasc Surg. 2011;54(5):1345- 1351. doi: 10.1016/j.jvs.2011.04.044

222. Chikhladze N.M. Arterial hypertension in patients with non-specific aortoarteritis. Systemic Hypertension. 2018;15(2):43-48 (in Russ). doi: 10.26442/2075-082X_2018.2.43-48.

223. Ying S., Sifan W., Yujiao W. et al. Clinical characteristics, imaging phenotypes and events free survival in Takayasu arteritis patients with hypertension. Arthritis Res Ther. 2021;23(1):196. Published 2021 Jul 21. doi: 10.1186/s13075-021-02579-8

224. Arabidze G.G., Abugova S.P., Matveeva L.S. et al. Clinical aspects of Takayasu’s disease (215 cases). Terapevt. Arhiv. 1980;5:124–129 (in Russ).

225. Maksimowicz-McKinnon K., Clark T.M., Hoffman G.S. Limitations of therapy and a guarded prognosis in an American cohort of Takayasu arteritis patients. Arthritis Rheum. 2007;56(3):1000-1009. doi:10.1002/art.22404

226. Erbel R., Aboyans V., Boileau C. et al. 2014 ESC Guidelines on the diagnosis and treatment of aortic diseases: Document covering acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult. The Task Force for the Diagnosis and Treatment of Aortic Diseases of the European Society of Cardiology (ESC). Eur Heart J. 2014 Nov 1;35(41):2873-926. doi: 10.1093/eurheartj/ehu281

227. Maz M., Chung S.A., Abril A. et al. 2021 American College of Rheumatology/ Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis. Arthritis Rheumatol. 2021 Aug;73(8):1349-1365. doi: 10.1002/art.41774

228. Águeda A.F., Monti S., Luqmani R.A. et al. Management of Takayasu arteritis: a systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis. RMD Open 2019;5:e001020. doi: 10.1136/rmdopen-2019-001020

229. Storzhakov G.I. Arterial hypertension in heart and aorta defects. In: Guide to Arterial Hypertension. Ed. E.I. Chazova, I.E. Chazovoi. - M.: Media Medica, 2005. - S. 1 (in Russ).

230. Клинические рекомендации. Коарктация аорты. МЗ РФ, 2020

231. Burakovsky V.I. et al. Congenital heart disease. In: Cardiovascular Surgery. Ed. Burakovsky V.I., Bokeria L.A. – M.: Medicine. 1996. - p. 299-312 (in Russ).

232. Pokrovsky A.V. Coarctation of the aorta. In: Diseases of the aorta and its branches. - M.: Medicine, 1979. - p. 269-302 (in Russ).

233. Hemels M.E., Hoendermis E.S., van Melle J.P. et al. Therapy refractory hypertension in adults: aortic coarctation has to be ruled out. Neth Heart J. 2011 Mar;19(3):107-111. doi: 10.1007/s12471-011-0074-8

234. Erbel R., Aboyans V., Boileau, C. et al. The Task Force for the Diagnosis and Treatment of Aortic Diseases of the European Society of Cardiology (ESC), European Heart Journal, Volume 35, Issue 41, 1 November 2014, Pages 2873–2926. doi: 10.1093/eurheartj/ehu281

235. Stout K.K., Daniels C.J., Aboulhosn J.A. et al. 2018 AHA/ACC guideline for the management of adults with congenital heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139:e698–e800. doi: 10.1161/CIR.0000000000000603

236. Hiratzka L.F., Bakris G.L., Beckman J.A. et al. 2010 ACCF/AHA/AATS/ ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with Thoracic Aortic Disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine [published correction appears in Circulation. 2010 Jul 27;122(4):e410]. Circulation. 2010;121(13):e266-e369. doi: 10.1161/CIR.0b013e3181d4739e

237. Ilin A.S., Teplov P.V., Sakovich V.A. Aorta coarctation as a pathology of cardiovascular system. Our potential in surgery. Siberian Medical Review.2018;(3): 24- 33 (in Russ.). doi: 10.20333/2500136-2018-3-24-33

238. Vohra H.A., Adamson L., Haw M.P. Does surgical correction of coarctation of the aorta in adults reduce established hypertension? Interact Cardiovasc Thorac Surg. 2009;8(1):123-127. doi:10.1510/icvts.2008.185736

239. Bhat M.A., Neelakandhan K.S., Unnikrishnan M. et al. Fate of hypertension after repair of coarctation of the aorta in adults. Br J Surg. 2001;88(4):536- 538. doi: 10.1046/j.1365-2168.2001.01745.x

240. Torok R.D., Campbell M.J., Fleming G.A. et al. Coarctation of the aorta: Management from infancy to adulthood. World J Cardiol. 2015;7(11):765- 775. doi: 10.4330/wjc.v7.i11.765

241. Parati G., Lombardi C., Hedner J. et al.; European Respiratory Society; EU COST ACTION B26 members. Position paper on the management of patients with obstructive sleep apnea and hypertension: joint recommendations by the European Society of Hypertension, by the European Respiratory Society and by the members of European COST (COoperation in Scientific and Technological research) ACTION B26 on obstructive sleep apnea. J Hypertens. 2012 Apr;30(4):633-46. doi: 10.1097/HJH.0b013e328350e53b

242. Sateia M.J. International classification of sleep disorders-third edition: highlights and modifications. Chest. 2014 Nov;146(5):1387-1394. doi: 10.1378/chest.14-0970

243. Young T., Palta M., Dempsey J. et al. Burden of sleep apnea: rationale, design, and major findings of the Wisconsin Sleep Cohort study. WMJ. 2009 Aug;108(5):246-9.

244. Benjafield A.V., Ayas N.T., Eastwood P.R. et al. Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature-based analysis. Lancet Respir Med. 2019;7:687–98. doi: 10.1016/S2213-2600(19)30198-5

245. Lindberg E., Gislason T. Epidemiology of sleep-related obstructive breathing. Sleep Med Rev. 2000 Oct;4(5):411-33. doi: 10.1053/smrv.2000.0118

246. Aksenova A.V., Elfimova E.M., Galitsin P.V. et al. Role of the Pulse Oximetry in the cardiologist’s practice. Systemic Hypertension. 2014;11(4):26–30 (in Russ.).

247. Bochkarev M.V., Korostovtseva L.S., Filchenko I.A. et al. Complaints on sleep breathing disorder and cardiovascular risk factors in Russian regions: data from ESSE-RF study. Russ. J. Cardiol. 2018;6:152–158 (In Russ).

248. Khokhrina A., Andreeva E., Degryse J.M. The prevalence of sleepdisordered breathing in Northwest Russia: The ARKHsleep study. Chron Respir Dis. 2020 Jan-Dec;17:1479973120928103. doi: 10.1177/1479973120928103

249. Nieto F.J., Young T.B., Lind B.K. et al. Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study. Sleep Heart Health Study. JAMA. 2000 Apr 12;283(14):1829- 36. doi: 10.1001/jama.283.14.1829. Erratum in: JAMA 2002 Oct 23- 30;288(16):1985.

250. Peppard P.E., Young T., Palta M. et al. Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med. 2000 May 11;342(19):1378-84. doi: 10.1056/NEJM200005113421901

251. Lavie P., Herer P., Hoffstein V. Obstructive sleep apnoea syndrome as a risk factor for hypertension: population study. BMJ. 2000 Feb 19;320(7233):479-82. doi: 10.1136/bmj.320.7233.479.

252. Tokunou T., Ando S.I. Recent advances in the management of secondary hypertension-obstructive sleep apnea. Hypertens Res. 2020 Dec;43(12):1338-1343. doi: 10.1038/s41440-020-0494-1

253. Sleep-related breathing disorders in adults: recommendations for syndrome definition and measurement techniques in clinical research. The Report of an American Academy of Sleep Medicine Task Force. Sleep. 1999 Aug 1;22(5):667-89.

254. Kapur V.K., Auckley D.H., Chowdhuri S. et al. Clinical Practice Guideline for Diagnostic Testing for Adult Obstructive Sleep Apnea: An American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med. 2017 Mar 15;13(3):479-504. doi: 10.5664/jcsm.6506

255. Somers V.K., White D.P., Amin R. et al. Sleep apnea and cardiovascular disease: an American Heart Association/American College of Cardiology Foundation Scientific Statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council on Cardiovascular Nursing. J Am Coll Cardiol. 2008 Aug 19;52(8):686-717. doi: 10.1016/j.jacc.2008.05.002

256. Johns M.W. Daytime sleepiness, snoring, and obstructive sleep apnea. The Epworth Sleepiness Scale. Chest. 1993 Jan;103(1):30-6. doi: 10.1378/chest.103.1.30

257. Jordan A.S., McSharry D.G., Malhotra A. Adult obstructive sleep apnoea. Lancet. 2014 Feb 22;383(9918):736-47. doi: 10.1016/S0140-6736(13)60734-5

258. Giles T.L., Lasserson T.J., Smith B.J. et al. Continuous positive airways pressure for obstructive sleep apnoea in adults. Cochrane Database Syst Rev. 2006 Jan 25;(1):CD001106. doi: 10.1002/14651858.CD001106. pub2. Update in: Cochrane Database Syst Rev. 2006;(3):CD001106.

259. Walia H.K., Thompson N.R., Pascoe M. et al. Effect of Positive Airway Pressure Therapy on Drowsy Driving in a Large Clinic-Based Obstructive Sleep Apnea Cohort. J Clin Sleep Med. 2019 Nov 15;15(11):1613-1620. doi: 10.5664/jcsm.8024

260. US Preventive Services Task Force. Screening for Obstructive Sleep Apnea in Adults: US Preventive Services Task Force Recommendation Statement. JAMA. 2022;328(19):1945–1950. doi: 10.1001/jama.2022.20304

261. Liu L., Cao Q., Guo Z. et al. Continuous positive airway pressure in patients with obstructive sleep apnea and resistant hypertension: a meta-analysis of randomized controlled trials. J Clin Hypertens (Greenwich). 2016 Feb;18(2):153-8. doi: 10.1111/jch.12639

262. Montesi S.B., Edwards B.A., Malhotra A. et al. The effect of continuous positive airway pressure treatment on blood pressure: a systematic review and meta-analysis of randomized controlled trials. J Clin Sleep Med. 2012 Oct 15;8(5):587-96. doi: 10.5664/jcsm.2170

263. Litvin A.Y., Sukmarova Z.N., Elfimova E.M. et al. Effects of CPAP on «vascular» risk factors in patients with obstructive sleep apnea and arterial hypertension. Vasc Health Risk Manag. 2013;9:229-235. doi: 10.2147/VHRM.S40231

264. Patil S.P., Ayappa I.A., Caples S.M. et al. Treatment of Adult Obstructive Sleep Apnea with Positive Airway Pressure: An American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med. 2019 Feb 15;15(2):335-343. doi: 10.5664/jcsm.7640

265. Epstein L.J., Kristo D., Strollo P.J Jr., et al. Adult Obstructive Sleep Apnea Task Force of the American Academy of Sleep Medicine. Clinical guideline for the evaluation, management and long-term care of obstructive sleep apnea in adults. J Clin Sleep Med. 2009 Jun 15;5(3):263-76.

266. Grossman A., Messerli F.H., Grossman E. Drug induced hypertension--An unappreciated cause of secondary hypertension. Eur J Pharmacol. 2015 Sep 15;763(Pt A):15-22. doi: 10.1016/j.ejphar.2015.06.027

267. Lovell A.R., Ernst M.E. Drug-Induced Hypertension: Focus on Mechanisms and Management. Curr Hypertens Rep. 2017 May;19(5):39. doi: 10.1007/s11906-017-0736-z. PMID: 28451850.

268. Aronow W.S. Drug-induced causes of secondary hypertension. Ann Transl Med. 2017 Sep;5(17):349. doi: 10.21037/atm.2017.06.16